Johnson & Johnson vs AbbVie: Safe Dividend or Higher Yield?

Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) are two pharmaceutical companies with different approaches to generating revenue. J&J has a 64-year dividend streak, a AAA-rated balance sheet, and diversified cash flows, making it the safer income pick.

AbbVie, on the other hand, pays a higher yield of 2.78%, but its portfolio is more concentrated in immunology, which carries more single-product risk. The company recently announced a $10.9 billion acquisition of Apogee Therapeutics, adding long-acting biologics for atopic dermatitis and respiratory disease.

J&J's Q2 earnings report showed strong revenue growth, with worldwide sales reaching $25.3 billion. AbbVie's quarter was also solid, with revenue increasing 10.2% to nearly $17 billion. However, the company's reliance on immunology products raises concerns about its long-term prospects.

While J&J is a more conservative choice for income investors, AbbVie offers the potential for higher returns, but at a higher risk. The next test for both companies will be their ability to sustain growth in the face of increasing competition and patent expirations.